Will Tirzepatide become a game-changer in the pharmacological treatment of obesity? - literature review
DOI:
https://doi.org/10.12775/JEHS.2024.71.49544Keywords
tirzepatide, anti-obesity drug, obesity, excessive body weight, GLP agonist, GIP-1 agonistAbstract
Introduction and objective: Obesity has become an important public health issue in Poland. Furthermore, it is one of the most common preventable causes of diseases and mortality. Pharmacological methods of treating obesity have been developing significantly in recent years.Tirzepatide is a new dual incretin receptor agonist that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. The aim of this review is to assess the effectiveness of this medication in reducing body weight.
Current state of knowledge: According to data from the Central Statistical Office (GUS) in Poland, 65% of men and 49% of women are struggling with the issue of excessive body weight [1]. Obesity in Polish society is steadily increasing in every age group. However, it affects most significantly children aged 7-13 years and adolescents. In 2022, the novel dual GLP and GIP-1 agonist has been registered for the treatment of type 2 diabetes which is not satisfactorily controlled. It can be also used together with diet and physical activity in patients diagnosed with obesity (BMI of 30 kg/m2 or more) or who are overweight (BMI 27-30 kg/m2) and have weight-related health problems such as hypertension, metabolic syndrome, dislipidaemia and diabetes mellitus [2].
Summary: The increasing prevalence of obesity leads to a dynamic search for the most effective pharmacological methods of treating obesity. The combined activation of GLP-1 and GIP receptors by Tirzepatide has been shown to have additional benefits beyond satisfying glucose control. The biological mechanism of action of this medication additionally causes decreased food intake, slowed gastric emptying and enhanced insulin secretion, all of which can contribute to weight reduction.
References
Stan zdrowia ludności Polski w 2019 roku. Główny Urząd Statystyczny. Wozniak S., dr Wieczorkowski R., Czekalska A.
ISBN 978-83-66466-56-2
Charakterystyka Produktu Leczniczego Mounjaro - roztwór do wstrzykiwań.
https://ec.europa.eu/health/documents/community-register/2023/20231211161235/anx_161235_pl
Olszanecka-Glinianowicz M., Mazur A., Chudek J., Kos-Kudła B., Markuszewski L., Dudek D., Major P., Małczak P., Tarnowski W., Jaworski P., Tomiak E.
Obesity in Adults: Position Statement of Polish Association for the Study on Obesity, Polish Association of Endocrinology, Polish Association of Cardiodiabetology, Polish Psychiatric Association, Section of Metabolic and Bariatric Surgery of the Association of Polish Surgeons and the College of Family Physicians in Poland.
https://doi.org/10.3390/nu15071641
Garvey, W.T., Mechanick, J.I., Brett, E.M., Garber, A.J., Hurley, D.L., Jastreboff, A.M., Nadolsky, K., Pessah-Pollack, R., Plodkowski, R. Reviewers of the AACE/ACE Obesity Clinical Practice Guidelines. American Association of Clinical Endocrinologist and American College
of Endocrinology Comprehensive Clinical Practice Guidelines
for Medical Care of Patients with Obesity 2016.
Ilow, R., Regulska-Ilow, B., Różańska, D., Zatońska, K., Dehghan, M., Zhang, X., Szuba, A., Vatten, L., Janik-Koncewicz K., Mańczuk M.
Assessment of dietary intake in a sample of Polish population - Baseline assessment from the prospective cohort ‘PONS’ study, 2011.
Bąk-Sosnowska M., Białkowska M., Bogdański P., Chomiuk T., Gałązka-Sobotka M., Holecki M., Jarosińska A., Jezierska M.,
Kamiński P., Kłoda K., Kręgielska-Narożna M., Lech M., Mamcarz A., Mastalerz-Migas A., Matyjaszek-Matuszek B., Ostrowska L., Płaczkiewicz-Jankowska E., Stachowska E., Stelmach-Mardas M., Szeliga J., Szulińska M., Walczak M., Wyleżoł M.
Zalecenia kliniczne dotyczące postępowania u chorych na otyłość 2022 – stanowisko Polskiego Towarzystwa Leczenia Otyłości, 2022.
Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1, 2018.
DOI: 10.1016/j.cmet.2018.03.001
Holst JJ. The physiology of glucagon-like peptide 1, 2007.
DOI: 10.1152/physrev.00034.2006
Sun, B., Willard F.S., Feng D., Alsina-Fernandez J., Chen Q.,Vieth M., Ho J. D., Showalter A. D., Stutsman C., Ding L.
Structural determinants of dual incretin receptor agonism by Tirzepatide, 2022.
Willard F. S., Douros J. D., Gabe M. B., Showalter A. D., Wainscott D. B., Suter T. M., Capozzi M. E., van der Velden W. J., Stutsman C., Cardona G. R. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist, 2020.
Forzano I., Fahimeh Varzideh F., Avvisato R., S Jankauskas S., Mone P., Santulli G. Tirzepatide: A Systematic Update, 2023.
DOI: 10.3390/ijms232314631
Rosenstock J., Wysham C., Frías J. P., Kaneko S., Lee C. J., Landó L. F., Mao H., Cui X., Karanikas C. A., Thieu V.
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1).
DOI: 10.1016/S0140-6736(21)01324-6
Jastreboff A. M., Aronne L. J., Ahmad N. N., Wharton S., Connery L., Alves B., Kiyosue A., Zhang S., Liu B., Bunck M. C., Stefanski A.,
SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of obesity.
DOI:10.1056/NEJMoa2206038.
Tirzepatide (Mounjaro) for type 2 diabetes. Med Lett Drugs Ther. 2022 Jul 11; 64(1654):105-107
Chavda V. P., Ajabiya J., Teli D., Bojarska J., Apostolopoulos V. Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity. A Mini-Review. Molecules. 2022 Jul 05;27(13)
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Aleksandra Doryń, Kinga Woźniak, Magdalena Jung, Maximilian Jung, Patryk Hedesz, Klaudia Warzycka, Monika Gardian-Baj, Alicja Szczerbiak, Wiktoria Ulicka, Katarzyna Kuśmierczyk, Karolina Maliszewska
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 403
Number of citations: 0
